INMB:NASDAQ, INmune Bio, Inc.

INMB stock overview

INmune Bio, Inc. (INMB:NASDAQ) closed at $1.33 on November 4, 2026, up 0.76% on the day. The stock trades 48.8% below its 52-week high of $2.60 and 22.0% above its 52-week low of $1.09. Over the past year, it lost 24.9%. INmune Bio, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price
$1.33
Day change
+0.76%
Volume
258,683
Average volume
327,678
Market cap
41M+
52-week range
$1.09 – $2.60
50-day average
$1.96
200-day average
$1.63

Price action over the past year

In 252 trading sessions since November 4, 2025, INMB closed higher on 111 days (44%). Its best day was May 14, 2026 (+15.07%) and its worst was January 28, 2026 (-10.56%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

INMB news

About INmune Bio, Inc.

INmune Bio Inc is a clinical stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's products include INKmune, INB03, and others.

Similar stocks

Find more stocks like INMB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.